Therapeutic and prophylactic applications of alphavirus vectors

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Expert Reviews in Molecular Medicine

• Publication date

  2008-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1017/S1462399408000859PMID 19000329
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A novel neurotropic expression vector based on the avirulent A7(74) strain of Semliki Forest virus

  2011cited by this paper
• Semliki Forest virus A7(74) transduces hippocampal neurons and glial cells in a temperature-dependent dual manner

  2011cited by this paper
• Development of a new noncytopathic Semliki Forest virus vector providing high expression levels and stability.

  2008cited by this paper
• Gene therapy progress and prospects cancer: oncolytic viruses

  2008cited by this paper
• Effect of intranasal administration of Semliki Forest virus recombinant particles expressing interferon-β on the progression of experimental autoimmune encephalomyelitis.

  2008cited by this paper
• Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.

  2008cited by this paper
• A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer

  2007cited by this paper
• Semliki Forest virus vectors expressing transforming growth factor beta inhibit experimental autoimmune encephalomyelitis in Balb/c mice.

  2007cited by this paper
• Restricted tissue tropism and acquired resistance to Sindbis viral vector expression in the absence of innate and adaptive immunity

  2007cited by this paper
• Semliki Forest virus vectors expressing the H and HN genes of measles and mumps viruses reduce immunity induced by the envelope protein genes of rubella virus.

  2007cited by this paper
• In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.

  2007cited by this paper
• Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.

  2007cited by this paper
• Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis

  2007cited by this paper
• Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge.

  2007cited by this paper
• Increased human immunodeficiency virus type 1 Env expression and antibody induction using an enhanced alphavirus vector.

  2007cited by this paper
• VRP immunotherapy targeting neu: treatment efficacy and evidence for immunoediting in a stringent rat mammary tumor model

  2007cited by this paper
• Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.

  2007cited by this paper
• A Novel Alphavirus Vaccine Encoding Prostate-Specific Membrane Antigen Elicits Potent Cellular and Humoral Immune Responses

  2007cited by this paper
• A Semliki Forest virus replicon vectored DNA vaccine expressing the E2 glycoprotein of classical swine fever virus protects pigs from lethal challenge.

  2007cited by this paper
• Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene — a phase I/II clinical protocol

  2007cited by this paper
• Heterologous Prime–Boost Strategy to Immunize Very Young Infants against Measles: Pre‐clinical Studies in Rhesus Macaques

  2007cited by this paper
• Oncolytic viruses in cancer therapy

  2007cited by this paper
• Biodistribution and tumor infectivity of semliki forest virus vectors in mice: effects of re-administration.

  2007cited by this paper
• Potential of alphavirus vectors in the treatment of advanced solid tumors.

  2007cited by this paper
• Increased Immunogenicity of a DNA-Launched Venezuelan Equine Encephalitis Virus-Based Replicon DNA Vaccine

  2007cited by this paper
• Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models

  2007cited by this paper
• Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice

  2007cited by this paper
• Cellular and Humoral Immune Responses to Alphavirus Replicon Vaccines Expressing Cytomegalovirus pp65, IE1, and gB Proteins

  2007cited by this paper
• The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans.

  2007cited by this paper
• Characterization of Immune Responses Elicited in Macaques Immunized Sequentially with Chimeric VEE/SIN Alphavirus Replicon Particles Expressing SIVGag and/or HIVEnv and with Recombinant HIVgp140Env Protein

  2006cited by this paper
• Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice.

  2006cited by this paper
• Deletions in the hypervariable domain of the nsP3 gene attenuate Semliki Forest virus virulence.

  2006cited by this paper
• Inhibition of murine K-BALB and CT26 tumour growth using a Semliki Forest virus vector with enhanced expression of IL-18.

  2006cited by this paper
• CNS gene therapy applications of the Semliki Forest virus 1 vector are limited by neurotoxicity.

  2006cited by this paper
• Growth inhibitory effect of triple anti-tumor gene transfer using Semliki Forest virus vector in glioblastoma cells.

  2006cited by this paper
• Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity

  2006cited by this paper
• Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice.

  2006cited by this paper
• High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

  2006cited by this paper
• Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy.

  2006cited by this paper
• Prime-boost immunization using DNA vaccine and recombinant Orf virus protects pigs against Pseudorabies virus (Herpes suid 1).

  2006cited by this paper
• Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles.

  2005cited by this paper
• Targeting Human Glioblastoma Cells: Comparison of Nine Viruses with Oncolytic Potential

  2005cited by this paper
• Inaugural Article: Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles

  2005cited by this paper
• Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660.

  2005cited by this paper
• Identification of amino acids of Sindbis virus E2 protein involved in targeting tumor metastases in vivo.

  2005cited by this paper
• An RNA Vaccine Based on Recombinant Semliki Forest Virus Particles Expressing the Cu,Zn Superoxide Dismutase Protein of Brucella abortus Induces Protective Immunity in BALB/c Mice

  2005cited by this paper
• Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice

  2005cited by this paper
• Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas.

  2005cited by this paper
• Biochemical and Immunogenic Characterization of Soluble Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Expressed by Semliki Forest Virus

  2005cited by this paper
• Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector

  2005cited by this paper
• Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12

  2005cited by this paper
• Vaccination with a Sindbis Virus-Based DNA Vaccine Expressing Antigen 85B Induces Protective Immunity against Mycobacterium tuberculosis

  2005cited by this paper
• Alphaviruses and their derived vectors as anti-tumor agents.

  2004cited by this paper
• Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein

  2004cited by this paper
• Immunogene Therapy of Recurrent Glioblastoma Multiforme with a Liposomally Encapsulated Replication-Incompetent Semliki Forest Virus Vector Carrying the Human Interleukin-12 Gene – A Phase I/II Clinical Protocol

  2004cited by this paper
• Systemic tumor targeting and killing by Sindbis viral vectors

  2004cited by this paper
• Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis

  2004cited by this paper
• Alphavirus vectors for cancer gene therapy (review).

  2004cited by this paper
• The use of a double subgenomic Sindbis virus expression system to study mosquito gene function: effects of antisense nucleotide number and duration of viral infection on gene silencing efficiency

  2004cited by this paper
• Using Sindbis Viral Vectors for Specific Detection and Suppression of Advanced Ovarian Cancer in Animal Models

  2004cited by this paper
• Treatment of Experimental Autoimmune Encephalomyelitis with a Neurotropic Alphavirus Vector Expressing Tissue Inhibitor of Metalloproteinase‐2

  2004cited by this paper
• Sindbis viruses and other alphaviruses as cause of human arthritic disease

  2004cited by this paper
• Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes.

  2004cited by this paper
• Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine.

  2003cited by this paper
• Induction of Primary Virus-Cross-Reactive Human Immunodeficiency Virus Type 1-Neutralizing Antibodies in Small Animals by Using an Alphavirus-Derived In Vivo Expression System

  2003cited by this paper
• An Alphavirus Replicon Particle Chimera Derived from Venezuelan Equine Encephalitis and Sindbis Viruses Is a Potent Gene-Based Vaccine Delivery Vector

  2003cited by this paper
• Alphavirus vectors for vaccine production and gene therapy

  2003cited by this paper
• Novel Semliki Forest virus vectors with reduced cytotoxicity and temperature sensitivity for long-term enhancement of transgene expression.

  2003influential reference
• Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7.

  2003cited by this paper
• Effect of intranasal administration of Semliki Forest virus recombinant particles expressing reporter and cytokine genes on the progression of experimental autoimmune encephalomyelitis.

  2003cited by this paper
• Immunogene Therapy of Recurrent Glioblastoma Multiforme with a Liposomally Encapsulated Replication-Incompetent Semliki Forest Virus Vector Carrying the Human Interleukin-12 gene – a phase I/II Clinical Protocol

  2003cited by this paper
• Vaccination with Recombinant Alphavirus or Immune-Stimulating Complex Antigen Against Respiratory Syncytial Virus1

  2002cited by this paper
• Immune protection against staphylococcal enterotoxin-induced toxic shock by vaccination with a Venezuelan equine encephalitis virus replicon.

  2002cited by this paper
• Evaluation of FIV protein-expressing VEE-replicon vaccine vectors in cats.

  2002cited by this paper
• Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses.

  2002cited by this paper
• Systemic, Mucosal, and Heterotypic Immune Induction in Mice Inoculated with Venezuelan Equine Encephalitis Replicons Expressing Norwalk Virus-Like Particles

  2002cited by this paper
• Alphavirus Vectors as Tools in Cancer Gene Therapy

  2002cited by this paper
• Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems.

  2001influential reference
• Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA.

  2001cited by this paper
• Induction of apoptosis in BCL‐2‐expressing rat prostate cancer cells using the Semliki Forest virus vector

  2001cited by this paper
• Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus.

  2001cited by this paper
• Individual and Bivalent Vaccines Based on Alphavirus Replicons Protect Guinea Pigs against Infection with Lassa and Ebola Viruses

  2001cited by this paper
• A recombinant Semliki Forest virus particle vaccine encoding the prME and NS1 proteins of louping ill virus is effective in a sheep challenge model.

  2001cited by this paper
• Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles.

  2001cited by this paper
• Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara.

  2001influential reference
• Expression of the Two Major Envelope Proteins of Equine Arteritis Virus as a Heterodimer Is Necessary for Induction of Neutralizing Antibodies in Mice Immunized with Recombinant Venezuelan Equine Encephalitis Virus Replicon Particles

  2000cited by this paper
• Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus.

  2000cited by this paper
• Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses.

  2000cited by this paper
• Vaccination of Macaques against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles

  2000cited by this paper
• Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles

  2000cited by this paper
• Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine.

  2000cited by this paper
• Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge.

  1999cited by this paper
• Semiliki forest virus vector carrying the bovine viral diarrhea virus NS3 (p80) cDNA induced immune responses in mice and expressed BVDV protein in mammalian cells.

  1999cited by this paper
• The molecular pathogenesis of Semliki Forest virus: a model virus made useful?

  1999cited by this paper
• Cell death mechanisms in the olfactory bulb of rats infected intranasally with Semliki Forest virus

  1999cited by this paper
• Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing Hantavirus structural genes in hamsters.

  1999cited by this paper
• Two-Helper RNA System for Production of Recombinant Semliki Forest Virus Particles

  1999cited by this paper
• Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice.

  1999cited by this paper
• Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.

  1998cited by this paper
• Enhancing immune responses using suicidal DNA vaccines

  1998cited by this paper

• Viral vectors: design and delivery for small RNA.

  2025cites this paper
• Enhancing protective immunity against SARS-CoV-2 with a self-amplifying RNA lipid nanoparticle vaccine.

  2024cites this paper
• Advanced nanoscale delivery systems for mRNA-based vaccines.

  2024cites this paper
• New Generation Self-Replicating RNA Vaccines Derived from Pestivirus Genome.

  2024cites this paper
• Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses

  2023cites this paper
• Surface decorated reporter-tagged chikungunya virus-like particles for clinical diagnostics and identification of virus entry inhibitors.

  2023cites this paper
• The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology.

  2023cites this paper
• Packaging, Purification, and Titration of Replication-Deficient Semliki Forest Virus-Derived Particles as a Self-Amplifying mRNA Vaccine Vector

  2022cites this paper
• Construction of a Chikungunya Virus, Replicon, and Helper Plasmids for Transfection of Mammalian Cells

  2022cites this paper
• Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases

  2022cites this paper
• Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform

  2021cites this paper
• Perspectives on RNA Vaccine Candidates for COVID-19

  2021cites this paper
• A Productive Expression Platform Derived from Host-Restricted Eilat Virus: Its Extensive Validation and Novel Strategy

  2021cites this paper
• SARS-CoV-2 Leading Vaccine Candidates: Progress and Development

  2020cites this paper
• Nanomedicine-based approaches for mRNA delivery.

  2020cites this paper
• Molecular docking studies of chloroquine and its derivatives against P23pro‐zbd domain of chikungunya virus: Implication in designing of novel therapeutic strategies

  2019cites this paper
• Contaminating viral sequences in high-throughput sequencing viromics: a linkage study of 700 sequencing libraries.

  2019cites this paper
• DNA and RNA Vaccines: Current Status, Quality Requirements and Specific Aspects of Preclinical Studies

  2019influential citation
• mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

  2019cites this paper
• ДНК- и РНК-вакцины: современное состояние, требования к качеству и особенности проведения доклинических исследований

  2019cites this paper
• Self-Amplifying Replicon RNA Delivery to Dendritic Cells by Cationic Lipids

  2018cites this paper
• Chapter 28 FUTURE PROSPECTS OF VACCINES AND ANTIBODIES IN BIODEFENSE

  2018cites this paper
• Enhanced Delivery of DNA or RNA Vaccines by Electroporation.

  2017cites this paper
• Fate of antigens encoded by Self-amplifying mRNA vaccines

  2017cites this paper
• Dendritic Cell Endocytosis Essential for Viruses and Vaccines

  2017cites this paper
• Self-Replicating RNA Vaccine Delivery to Dendritic Cells.

  2017cites this paper
• Porcine reproductive and respiratory syndrome virus envelope (E) protein interacts with mitochondrial proteins and induces apoptosis

  2016cites this paper
• Molecular determinants of alphavirus neuropathogenesis in mice.

  2016cites this paper
• Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines.

  2016cites this paper
• Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 project.

  2016cites this paper
• Vectorisation de petits acides nucléiques par des lipopolyplexes : application au cancer du sein

  2016cites this paper
• Improving the Delivery and Replication of Oncolytic Viruses

  2016cites this paper
• Studies on inducible alphavirus-based antitumour strategy mediated by site-specific delivery with activatable cell-penetrating peptides

  2015cites this paper
• Transgenic DNA modules with pre-programmed self-destruction: Universal molecular devices to escape 'genetic litter' in gene and cell therapy.

  2015cites this paper
• Dendritic Cell Targets for Self-Replicating RNA Vaccines

  2015influential citation
• Self-amplifying mRNA vaccines.

  2015cites this paper
• Programmable insect cell carriers for systemic delivery of integrated cancer biotherapy.

  2015cites this paper
• CD8 T‐cell priming upon mRNA vaccination is restricted to bone‐marrow‐derived antigen‐presenting cells and may involve antigen transfer from myocytes

  2015cites this paper
• KALLE PÄRN Studies on inducible alphavirus-based antitumour strategy mediated by site-specific delivery with activatable cell-penetrating peptides

  2015influential citation
• DNA-Launched Alphavirus Replicons Encoding a Fusion of Mycobacterial Antigens Acr and Ag85B Are Immunogenic and Protective in a Murine Model of TB Infection

  2015cites this paper
• Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines

  2014cites this paper
• Self-replicating Replicon-RNA Delivery to Dendritic Cells by Chitosan-nanoparticles for Translation In Vitro and In Vivo

  2014cites this paper
• Semliki Forest Virus Expression System

  2014cites this paper
• Self-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic Nanoparticles

  2014cites this paper
• Mutations Conferring a Noncytotoxic Phenotype on Chikungunya Virus Replicons Compromise Enzymatic Properties of Nonstructural Protein 2

  2014cites this paper
• Dissection of virus-host cell interactions in the early response to infection

  2014cites this paper
• A cationic nanoemulsion for the delivery of next-generation RNA vaccines.

  2014cites this paper
• Trial Watch

  2013cites this paper
• Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ

  2013cites this paper
• Metabolic pathways recruited in the production of a recombinant enveloped virus: mining targets for process and cell engineering.

  2013cites this paper
• Genome-wide RNAi screen identifies SEC61A and VCP as conserved regulators of Sindbis virus entry.

  2013cites this paper
• A Vaccinia Virus Recombinant Transcribing an Alphavirus Replicon and Expressing Alphavirus Structural Proteins Leads to Packaging of Alphavirus Infectious Single Cycle Particles

  2013cites this paper
• Engineered alphavirus replicon vaccines based on known attenuated viral mutants show limited effects on immunogenicity.

  2013cites this paper
• A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer.

  2013cites this paper
• Functional analysis of viral and host components of alphavirus replicase complexes

  2013cites this paper
• RNA: the new revolution in nucleic acid vaccines.

  2013cites this paper
• Gene therapy : what it is , what it is not and what it will be

  2013cites this paper
• Studies on the Semliki Forest virus replicase protein nsP1

  2013influential citation
• Development and analysis of novel alphavirus-based multifunctional gene therapy and expression systems

  2013cites this paper
• Composition à base d'une particule de type viral

  2013cites this paper
• NELE TAMBERG Studies on Semliki Forest virus replication and pathogenesis

  2012influential citation
• Functional RNA delivery targeted to dendritic cells by synthetic nanoparticles.

  2012cites this paper
• Summary and Perspectives

  2012cites this paper
• Alphaviral nonstructural protease and its polyprotein substrate: arrangements for the perfect marriage

  2012cites this paper
• Phoenix rising: gene therapy makes a comeback

  2012cites this paper
• Nonviral delivery of self-amplifying RNA vaccines

  2012cites this paper
• Prime–boost approaches to tuberculosis vaccine development

  2012cites this paper
• Rubella virus-like replicon particles: analysis of encapsidation determinants and non-structural roles of capsid protein in early post-entry replication.

  2012influential citation
• The impact of vaccines and vaccinations: Challenges and opportunities for modelers.

  2011cites this paper
• Alphavirus Particle-Based Vaccine Vectors

  2011cites this paper
• The genetics of alphaviruses

  2011cites this paper
• A perspective on the 2009 A/H1N1 influenza pandemic in Mexico.

  2011cites this paper
• Prime‐boost vaccinations using recombinant flavivirus replicon and vaccinia virus vaccines: an ELISPOT analysis

  2011cites this paper
• Immunogenic and replicative properties of classical swine fever virus replicon particles modified to induce IFN-α/β and carry foreign genes.

  2011cites this paper
• Regulation of memory CD8 T cell differentiation

  2011cites this paper
• Packaging of porcine reproductive and respiratory syndrome virus replicon RNA by a stable cell line expressing its nucleocapsid protein

  2011cites this paper
• A Semliki Forest virus vector engineered to express IFNα induces efficient elimination of established tumors

  2011cites this paper
• Novel viral vectors utilizing intron splice-switching to activate genome rescue, expression and replication in targeted cells

  2011influential citation
• Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines

  2011cites this paper
• Progress in Respiratory Virus Vaccine Development

  2011cites this paper
• Biological challenges and technological opportunities for respiratory syncytial virus vaccine development

  2011cites this paper
• The Immunosuppressive Tumor Environment Is the Major Impediment to Successful Therapeutic Vaccination in Neu Transgenic Mice

  2010cites this paper
• In Vitro and In Vivo Characterization of MicroRNA-Targeted Alphavirus Replicon and Helper RNAs

  2010cites this paper
• Translation driven by picornavirus IRES is hampered from Sindbis virus replicons: rescue by poliovirus 2A protease.

  2010cites this paper
• Development and characterization of promoterless helper RNAs for the production of alphavirus replicon particle

  2010cites this paper
• RNA Replicons - A New Approach for Influenza Virus Immunoprophylaxis

  2010cites this paper
• Terapia gênica: o que é, o que não é e o que será

  2010cites this paper
• Adenoviral transfer in the liver: a novel in vivo simulation model in the rat

  2010cites this paper
• Update on the current status of cytomegalovirus vaccines

  2010cites this paper
• Short Communication Development and characterization of promoterless helper RNAs for the production of alphavirus replicon particle

  2010cites this paper
• Novel oncolytic viruses: riding high on the next wave?

  2010cites this paper
• TARTU ÜLIKOOL LOODUS- JA TEHNOLOOGIATEADUSKOND MOLEKULAAR- JA RAKUBIOLOOGIA INSTITUUT

  2009cites this paper
• Gene and Virotherapy Against Osteosarcoma

  2009cites this paper
• A structural and functional perspective of alphavirus replication and assembly.

  2009cites this paper
• Vaccines: the Fourth Century

  2009cites this paper
• Properties and use of novel replication-competent vectors based on Semliki Forest virus

  2009cites this paper
• Semliki Forest virus based vectors and cell lines for studying the replication and interactions of alphaviruses and hepaciviruses

  2009cites this paper
• Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

  2009cites this paper
• Progress in respiratory virus vaccine development.

  2007cites this paper